Steris Plc

Steris Plc

STE

Get informed when a big investor buys or sells

+ Follow
Market Cap$19.75B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Steris PlcSteris Plc25.41.24%11%3.40.3

Earnings Call Q4 2026

May 12, 2026 - AI Summary

FY26 performance was strong; Q4 lighter than expected - Q4 (continuing ops): total revenue +7% YoY; constant-currency organic +5% (driven by volume plus ~230 bps price). Gross margin 44% (down 30 bps YoY); EBIT margin 24.2% (a high but -60 bps YoY mainly from inflation/tariffs). - Tariffs impact: ~$10M in Q4 (better than expected) due to lower-than-expected outside-US volumes; incremental tariffs in FY26 = ~$46M, with total tariff spend modeled/expected FY26 between $60M–$65M. - Earnings/taxes: adjusted EPS $2.83 (+3% YoY); effective tax rate rose (Q4 25.4% vs 23.5% prior year). Company expects tax pressure to continue from withholding taxes tied to moving capital across borders.
FY26 full-year delivered record momentum and exceptional cash flow - FY26 growth: revenue +9%; constant-currency organic +7%; translated to 10% adjusted EPS growth despite tariff margin pressure (~80 bps margin trim from tariffs; Dan noted FY26 tariff spending trimmed margins ~80 bps overall). - Business milestones: all segments reached new highs—Healthcare +9% reported / +8% organic, Service +12%, Consumables +7%, Capital equipment +6%; AST +10% reported / +7% organic (services had softer Q4); Life Sciences +9% reported / +7% organic (driven by capital equipment +15%, consumables steady +8%). - Free cash flow: FY26 $982.9M (exceptional), helped by higher earnings more than offsetting much lower working-capital contribution vs FY25 (FY25 working capital benefited from inventory reductions after supply-chain issues). - Balance sheet: $1.9B total debt, gross debt/EBITDA ~1.2x (well below 2.0x–2.5x target).
FY27 outlook: moderate revenue growth, margin expansion modest, EPS up mid/high single digits - Revenue outlook (as-reported): +7% to +8% in FY27. FX slightly favorable; tuck-in acquisitions add inorganic revenue (~$45M combined to FY27). - Organic growth: 6% to 7% constant-currency, assuming ~200 bps price. - Segment organic targets: Healthcare & Life Sciences: 6% to 7%; AST: 7% to 8% (company is more conservative on AST early in the year due to inventory management/cautious med-tech customer behavior and difficult comps after strong prior-year periods). - Margins & EPS: EBIT margin expected to expand ~50 bps at the high end (assumes tariffs flat YoY + bonus tailwind from incentive comp). FY27 EPS guidance $11.10–$11.30 (~+9% to +11% vs FY26). - Cash flow/CapEx: FY27 free cash flow ~$850M; CapEx ~$375M. Working capital expected to grow in line with volumes (no repeat of FY26 working-capital tailwind).

Exclusive for Stockcircle Pro members

Sign upSign Up
$269.50

Target Price by Analysts

32.6% upsideSteris Plc Target Price DetailsTarget Price
$411.75

Current Fair Value

102.6% upside

Undervalued by 102.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$19.75 Billion
Enterprise Value$21.24 Billion
Dividend Yield$2.52 (1.24%)
Earnings per Share$7.93
Beta0.92
Outstanding Shares98,000,000

Return

Return on Equity10.87%ROE
Return on Assets7.29%
Return on Invested Capital11.49%

Valuation & Multiples

P/E Ratio25.38P/E Ratio
PEG49.54PEG
Price to Sales3.39Price to Sales
Price to Book Ratio2.78Price to Book Ratio
Enterprise Value to Revenue3.58
Enterprise Value to EBIT19.28
Enterprise Value to Net Income27
Total Debt to Enterprise0.09
Debt to Equity0.27Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 20, 2026
EPS Estimate
$2.85
Average shareholder expectation
Revenue Estimate
$1.59 B
Average shareholder expectation

Next Earnings Call

Expected Date
August 5, 2026
EPS Estimate
$2.52
Average shareholder expectation
Revenue Estimate
$1.50 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3739▼ 352.19%
Total Calls57,500▲ 122.01%
Total Puts21,497▼ 78.69%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %95.32%▲ 1.06%
Total Invested$20.78B▼ 11.37%
Investors Holding843▼ 56.00%

ESG Score

No data

About Steris Plc

CEO: Walter Rosebrough

Relevant Senate Committees

Joint Committee on Taxation

This committee provides critical analysis and revenue estimates for all tax legislation, directly influencing corporate tax structures and capital investment credits, which profoundly impact Steris Plc's financial planning and overall tax burden.

Finance

This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy directly affect Steris Plc's profitability, while Medicare pricing and trade policies can significantly influence its healthcare customers' reimbursement and global supply chain costs.

Appropriations

This committee directly allocates discretionary federal spending. Its subcommittees determine the specific funding for healthcare programs, research, and facilities, directly impacting the demand and order books for Steris Plc's products purchased by government entities.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA, which is the primary regulatory body for medical devices. Its oversight of the FDA and NIH funding directly impacts Steris Plc's product approvals, research, and market access.

Judiciary

This committee's oversight of antitrust laws and intellectual property is highly relevant to Steris Plc, impacting potential mergers and acquisitions, and protecting its medical device patents and innovations.

Veterans' Affairs

This committee directly impacts government healthcare contractors and medical device manufacturers like Steris Plc through its funding decisions for the Department of Veterans Affairs, which is a key customer base for medical supplies and equipment.